User Profile
Select your user profile

Multiplate® analyzer

A reliable tool for testing platelet function1
IVD For in vitro diagnostic use.
Multiplate® analyzer

Multiplate® analyzer
speech-bubble

Contact Roche

Contact a Roche representative. Do you have questions about our products or services? We're here to help! Contact us today.

Form Successfully Submitted!
Thank you for your submission!
text

Product introduction

The Multiplate analyzer is an easy to use instrument to determine platelet function in small quantities of whole blood, in a highly standardized manner. Whole blood is the physiological environment where platelet function takes place in vivo. The use of whole blood for in vitro testing eliminates the need for time-consuming centrifugation steps.

The term “Multiplate” is derived from the phrase “multiple platelet function analyzer”. The testing method is called multiple electrode aggregometry (MEA). Impedance aggregometry was developed by Cardinal and Flower for the assessment of platelet function in whole blood.2

The 5 channel analyzer, with CE marked tests (ADPtest, ASPItest, TRAPtest, ADP HS)3, has been featured by almost 700 Medline-listed articles and has been reported by several groups to be useful in tailoring antiplatelet therapy, as well as improving the management of bleeding complications in surgical procedures.4,5

Explore the Multiplate® analyzer

Product image for Multiplate® analyzer
Multiplate analyzer

Benefits of platelet function testing

Blood platelets or thrombocytes play a vital role in hemostasis, where they provide the initial primary hemostatic plug at the site of vessel injury to prevent bleeding. A variety of disorders of platelets, both inherited and acquired, can lead to a bleeding diathesis, which can be diagnosed using platelet function analysis1.

Platelets are also involved in thrombotic disorders and some rare inherited disorders, although the most common clinically are in cardiac disease (Myocardial Infarction) and thrombotic stroke. Development of arterial platelet thrombosis in myocardial infarcts is a leading cause of mortality in western society. To reduce the risk of thrombosis in these patients, antiplatelet medication like Aspirin and the P2Y12 platelet inhibitors clopidogrel, prasugrel and ticagrelor is administered to reduce platelet function. In some patients their response to these antiplatelet agents can be variable, with 30% of patients found as non-responders to clopidogrel4.

Platelet function testing can be used to monitor the efficacy of drugs and transition the change to other more effective antiplatelet drugs in non-responders or the de-escalation from one drug to another to reduce the bleeding risk5,6.

Platelet function testing can be performed in the following clinical scenarios; analysis of platelet function in patients ho have been on antiplatelet medication before cardiac surgery as part of the anesthetic work up to reduce bleeding risk or allowing patients to go for surgery sooner7. Monitoring of platelet function antagonists like Aspirin, clopidogrel, prasugrel and ticagrelor in patients at high thrombotic risk or who require de-escalation from one antiplatelet agent to another to reduce bleeding risk 4, 5, 7.

Heparin Induced Thrombocytopenia is another rare, but life-threatening thrombotic disorder, that can be diagnosed via platelet function testing and has been standardized by the ISTH SSC Platelet Immunology committee8

Platelet function testing supports clinical decision making in:

  • Percutaneous Coronary Interventions (PCI)5,6
  • Pre-Cardiac surgery9
  • De-escalation of antiplatelet treatment7
  • Heparin Induced Thrombocytopenia8
multiplate-reagents-chart

References

  1. Clinical and Laboratory Standards Institute. H58-A: Platelet Function Testing by Aggregometry; Approved Guideline. 1st ed. Clinical and Laboratory Standards Institute; 2008.
  2. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980;3(2):135-58.
  3. Method sheets: ASPItest (2023-02, V3), ADPtest (2023-02, V3), TRAPtest (2022-03, V3) and Prostaglandin E1 Reagent (2022-03, V2).
  4. Davidson S. Monitoring of antiplatelet therapy. Methods Mol Biol. 2023:2663:381-402.
  5. Sibbing D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521-1537.
  6. Geisler T, et al High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS One. 2015;10(8):e0135037.
  7. Sibbing D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747-1757.
  8. Morel-Kopp et al. Subcommittee on Platelet Immunology. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14: 2548–52.
  9. Kong R, et al. Consensus recommendations for using the Multiplate(®) for platelet function monitoring before cardiac surgery. Int J Lab Hematol. 2015;37(2):143-7.

 

Not for diagnostic use in the US.

 

Overview

Ordering Information

System specifications

  • High throughput

    30 tests/hour

  • Sample

    Whole blood sample anticoagulated with hirudin eliminates need for sample preparation, reduces risk of pre-analytical errors

  • Low sample volume

    only 300 μL whole blood per analysis

  • Fast turn-around time

    10 min./test

  • Easy to use

    only 3 pipetting steps

error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Related Products